Merck’s pembrolizumab plus chemotherapy showed sustained survival benefit versus chemotherapy alone
In first-line metastatic NSCLC, KEYTRUDA-based regimens have now shown a five-year survival benefit in four trials
In first-line metastatic NSCLC, KEYTRUDA-based regimens have now shown a five-year survival benefit in four trials
Subscribe To Our Newsletter & Stay Updated